Business
Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
(TheNewswire) Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using A...
About this update from Neurothera Labs Inc.
[{"type":"text","content":"Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA \n(TheNewswire)\n\n\nProprietary Cannabinoid-Enhanced\nPlatform Targets Antibiotic Resistance Using Approved Antimicrobials\n\n\n\nFebruary 2, 2026 – TheNewswire\n- Vancouver, British Columbia, Canada-\nNeurothera Labs Inc. (TSXV: NTLX) (“Neurothera” or the “Company”), a clinical-stage biotech company\nand a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC)\n(“SciSparc”), today announced that the United States Patent and\nTrademark Office has granted a U.S. patent for its proprietary\ncombination of antimicrobials and cannabinoids. This patent covers\ninnovative compositions and methods of potentiating antimicrobials,\nspecifically designed to enhance the efficacy of existing antibiotics\nagainst resistant bacterial strains.\n\n\nThis patent grant in the United States joins previously\ngranted patents for the same family in the U.S., Europe, further\nstrengthening the global intellectual property protection of\nNeurothera's proprietary antimicrobial-potentiating\nplatform.\n\n\nThe patented technology combines well-established\nantibiotics—many of which have been on the market for decades—with\ncannabinoids such as THC (Δ⁹-Tetrahydrocannabinol) and CBD\n(Cannabidiol), and in certain embodiments, N-acylethanolamines like\npalmitoylethanolamide (PEA). This synergistic approach, which used the\nCompany’s combination of antimicrobials and\ncannabinoids, demonstrated in pre- clinical studies, enhances antimicrobial activity, potentially restoring the\neffectiveness of antibiotics that are ineffective as monotherapy\nagainst resistant Gram-positive pathogens, such as Methicillin-resistant Staphylococcus aureus (“MRSA”). When administered in combination with cannabinoids,\nthe platform leverages the extensive long-term safety data of these\nantibiotics to help minimize risk, potentially offering an effective,\nsafe, and affordable therapeutic solution.\n\n\nProlonged and widespread antibiotic use has driven the\nemergence of resistant bacterial strains through genetic mutations and\nselective pressure. MRSA remains a leading global threat, evading\nmultiple antibiotic classes. According to a comprehensive analysis in\nTh...